Trident Lifeline Limited was originally incorporated as Private Limited Company under the name 'Trident Lifeline Private Limited' on January 09, 2014. Subsequently, Company converted into a Public Limited pursuant to Shareholders' Resolution on June 02, 2022 and name of Company was changed to 'Trident Lifeline Limited' on June 10, 2022. The Company is engaged in business of marketing ethical pharmaceutical products in domestic as well as international market. It is also engaged in distribution of pharmaceutical products through third party distribution network. Apart from these, the Company offer wide range of pharmaceutical formulations and products manufactured on contract manufacturing under loan license. It operate in India as well as African, Latin American and East Indian Countries. Presently, it has presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanamar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, Venezuela. Presently, Company operates with one contract manufacturer, who maintained relationship with the regular supplier, having FDA and WHO approved plant to supply pharma formulations. These units manufacture tablets, capsules, dry powder, syrup under their own brands. Pharma business operations are supported by various contract manufacturers having facilities which are approved by FDA/WHO and other relevant authorities. The Company typically work on contract manufacturing basis or at times purchase order basis, depending upon customer's requirement, with manufacturer of pharma products. The Company deal in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. The product portfolio comprises of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steriodal anti-inflammatory drug (NSAIDS). The Company had Certified its Quality Management System Under the Certificate ISO 9001: 2015 in FY 2021. Besides, product portfolio consists of 832 products, which operated under different brand names across the globe as on May 31, 2022. As on May 31, 2022, the Company has 267 products registered in total 8 countries, of which total 565 products are under process of registration in 11 countries.